obesity drug news today glp-1 october 21 2025 Market Myths & Facts: GLP-1 Drugs
Description
Oviva scaled their DiGA adoption to 125k prescriptions last year
An updated literature review
As the insulinotropic effects are glucose-dependent and the counterregulatory response of glucagon to hypoglycaemia remains intact with GLP-1 infusion [19], the risk of hypoglycaemia is low
Therefore, it is imperative for clinicians to remain aware of emerging evidence and advancements in this dynamic therapeutic domain (See Figures 4 and 5)
Indeed, in January 2025, the Surgeon General of the United States released a report raising awareness of the links between cancer and alcohol consumption 4
